Oncolytics Biotech® Inc.'s Research Collaborators to Present Data on REOLYSIN® Clinical Trials
News May 15, 2009
Oncolytics Biotech Inc. has announced that data from three clinical trials using REOLYSIN are scheduled to be presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting. The meeting will take place in Orlando, Florida May 29-June 2, 2009. The abstracts are available on the ASCO website at www.asco.org.
REOLYSIN poster presentations:
Dr. Monica Mita and colleagues are scheduled to deliver a poster presentation entitled "A Phase II Study of Intravenous (IV) Wild-Type Reovirus in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung."
Dr. Johann de Bono and colleagues are scheduled to deliver a poster presentation entitled "A Phase I Study of the Combination of Intravenous Reolysin (REO) and Gemcitabine (GEM) in Patients (pts) with Advanced Cancer."
Dr. Sanjay Goel and colleagues are scheduled to deliver a poster entitled "Dose Escalation and Pharmacodynamic Study of Intravenous Administration of REOLYSIN, a Live Replication Competent RNA Virus in Patients with Advanced Solid Tumors."
15th International Conference on Surgical Pathology and Cancer Diagnosis
Apr 15 - Apr 16, 2019